These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 35546501)

  • 1. A Bayesian platform trial design to simultaneously evaluate multiple drugs in multiple indications with mixed endpoints.
    Zhao Y; Tang RS; Du Y; Yuan Y
    Biometrics; 2023 Jun; 79(2):1459-1471. PubMed ID: 35546501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A generalized calibrated Bayesian hierarchical modeling approach to basket trials with multiple endpoints.
    Chi X; Yuan Y; Yu Z; Lin R
    Biom J; 2024 Mar; 66(2):e2300122. PubMed ID: 38368277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shotgun: A Bayesian seamless phase I-II design to accelerate the development of targeted therapies and immunotherapy.
    Jiang L; Li R; Yan F; Yap TA; Yuan Y
    Contemp Clin Trials; 2021 May; 104():106338. PubMed ID: 33711459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Bayesian phase I/II platform design for co-developing drug combination therapies for multiple indications.
    Mu R; Xu J; Tang RS; Kopetz S; Yuan Y
    Stat Med; 2022 Jan; 41(2):374-389. PubMed ID: 34730248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bayesian cluster hierarchical model for subgroup borrowing in the design and analysis of basket trials with binary endpoints.
    Chen N; Lee JJ
    Stat Methods Med Res; 2020 Sep; 29(9):2717-2732. PubMed ID: 32178585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PMED: Optimal Bayesian Platform Trial Design with Multiple Endpoints.
    He T; Liu R; Liu M; Lin J
    J Biopharm Stat; 2022 Jul; 32(4):567-581. PubMed ID: 36000260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. rBMA: A robust Bayesian Model Averaging Method for phase II basket trials based on informative mixture priors.
    Wang X; Wei W
    Contemp Clin Trials; 2024 May; 140():107505. PubMed ID: 38521384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Bayesian phase II proof-of-concept design for clinical trials with longitudinal endpoints.
    Zhang W; Laird G; Chen J; Yuan Y
    Stat Med; 2024 Jan; 43(1):173-183. PubMed ID: 37937591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bayesian sample size determination in basket trials borrowing information between subsets.
    Zheng H; Grayling MJ; Mozgunov P; Jaki T; Wason JMS
    Biostatistics; 2023 Oct; 24(4):1000-1016. PubMed ID: 35993875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Bayesian basket trial design using a calibrated Bayesian hierarchical model.
    Chu Y; Yuan Y
    Clin Trials; 2018 Apr; 15(2):149-158. PubMed ID: 29499621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variance prior specification for a basket trial design using Bayesian hierarchical modeling.
    Cunanan KM; Iasonos A; Shen R; Gönen M
    Clin Trials; 2019 Apr; 16(2):142-153. PubMed ID: 30526008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hierarchical Bayesian clustering design of multiple biomarker subgroups (HCOMBS).
    Kang D; S Coffey C; J Smith B; Yuan Y; Shi Q; Yin J
    Stat Med; 2021 May; 40(12):2893-2921. PubMed ID: 33772843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bayesian methods for the analysis of early-phase oncology basket trials with information borrowing across cancer types.
    Jin J; Riviere MK; Luo X; Dong Y
    Stat Med; 2020 Nov; 39(25):3459-3475. PubMed ID: 32717103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RoBoT: a robust Bayesian hypothesis testing method for basket trials.
    Zhou T; Ji Y
    Biostatistics; 2021 Oct; 22(4):897-912. PubMed ID: 32061093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ComPAS: A Bayesian drug combination platform trial design with adaptive shrinkage.
    Tang R; Shen J; Yuan Y
    Stat Med; 2019 Mar; 38(7):1120-1134. PubMed ID: 30419609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of Bayesian information borrowing methods in basket trials and a novel proposal of modified exchangeability-nonexchangeability method.
    Daniells L; Mozgunov P; Bedding A; Jaki T
    Stat Med; 2023 Oct; 42(24):4392-4417. PubMed ID: 37614070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IBIS: identify biomarker-based subgroups with a Bayesian enrichment design for targeted combination therapy.
    Chen X; Zhang J; Jiang L; Yan F
    BMC Med Res Methodol; 2023 Mar; 23(1):66. PubMed ID: 36941537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using dichotomized survival data to construct a prior distribution for a Bayesian seamless Phase II/III clinical trial.
    Duputel B; Stallard N; Montestruc F; Zohar S; Ursino M
    Stat Methods Med Res; 2023 May; 32(5):963-977. PubMed ID: 36919403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bayesian order constrained adaptive design for phase II clinical trials evaluating subgroup-specific treatment effect.
    Shan M; Guo B; Liu H; Li Q; Zang Y
    Stat Methods Med Res; 2023 May; 32(5):885-894. PubMed ID: 36919375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.